当前吸烟者:影响慢阻肺疾病进展和治疗应答的临床表型
本综述讨论吸烟对慢阻肺病理生理及临床的影响。吸烟是发达国家慢阻肺主要已知病因,约占80%的病例;活动性吸烟者较已戒烟者病情更重、肺功能下降更快且生活质量更差。吸烟还会损害慢阻肺药物疗效,尤其是吸入性糖皮质激素和大环内酯类药物。
要点
- 活动性吸烟者较已戒烟者肺功能下降更快、生活质量更差。
- 吸烟可损害慢阻肺药物疗效,尤其吸入激素和大环内酯类。
- 全球吸烟率范围为3%至37%,受性别、年龄、种族等因素影响。
核心结论
- 当前吸烟是影响慢阻肺疾病进展和治疗应答的重要临床表型。
- 活动性吸烟者较已戒烟者病情更重、肺功能下降更快且生活质量更差。
- 吸烟会损害慢阻肺药物疗效,尤其是吸入性糖皮质激素和大环内酯类药物。
研究设计与样本
- 综述,讨论吸烟对慢阻肺病理生理及临床影响。
主要发现
- 在发达国家,吸烟是慢阻肺的主要已知病因,约占80%的病例。
- 活动性吸烟者较已戒烟者病情更重,肺功能下降更快,生活质量更差。
- 全球吸烟率范围为3%至37%,受性别、年龄、种族、教育和地理等因素影响。
- 吸烟会损害慢阻肺药物疗效,尤其是吸入性糖皮质激素和大环内酯类药物。
临床怎么用
- 临床应识别当前吸烟的慢阻肺患者,关注其更快的疾病进展和更差的治疗应答。
- 对当前吸烟者使用吸入性糖皮质激素和大环内酯类药物时需考虑吸烟对疗效的损害。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition of the lungs characterized by chronic respiratory symptoms, primarily dyspnea, cough, and sputum production, due to airway and/or alveoli abnormalities that cause persistent, and often progressive, airflow obstruction. Although the underlying mechanisms responsible for COPD remain poorly understood, over the past several decades, clinical phenotypes and endotypes have been suggested. These include frequent exacerbator and eosinophilic groups that guide tailored therapies for patients with that clinical expression. In the developed world, smoking is the main known cause of COPD, responsible for ∼80% of cases. Active smokers have more severe disease, with more rapid lung function decline and impaired quality of life, than former smokers. Unfortunately, smoking is still highly prevalent. Rates range between 3% and 37% globally, with factors including sex, age, race, education, and geography influencing the rate of addiction. Importantly, several studies have shown that smoking detrimentally affects treatment efficacy of COPD medications; this is particularly true of inhaled corticosteroids and macrolides. In this review, we discuss the effects of smoking on the pathophysiology of COPD and the clinical impact of smoke exposure in patients with COPD.
引用
- Celli BR, Christenson SA, Rabe KF, et al. Current Smoker: A Clinical Chronic Obstructive Pulmonary Disease Phenotype Affecting Disease Progression and Response to Therapy. Am J Respir Crit Care Med. 2025. PMID: 39938077. doi:10.1164/rccm.202407-1379CI
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。